Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection

J Clin Gastroenterol. 2016 Oct;50(9):799. doi: 10.1097/MCG.0000000000000587.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • 2-Naphthylamine
  • Alanine Transaminase / blood
  • Anilides / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Aspartate Aminotransferases / blood
  • Carbamates / therapeutic use
  • Cyclopropanes
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / enzymology*
  • Humans
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / therapeutic use
  • Middle Aged
  • Proline / analogs & derivatives
  • Ribavirin / therapeutic use
  • Ritonavir / therapeutic use
  • Sulfonamides / therapeutic use
  • Uracil / analogs & derivatives
  • Uracil / therapeutic use
  • Valine
  • Withholding Treatment*

Substances

  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Sulfonamides
  • ombitasvir
  • Ribavirin
  • Uracil
  • Proline
  • 2-Naphthylamine
  • dasabuvir
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Valine
  • Ritonavir
  • paritaprevir